Personalized Surgery for Gastric Adenocarcinoma: A Meta-analysis of D1 versus D2 Lymphadenectomy

Annals of Surgical Oncology

Volumn 22, Issue 6, 2015, Pages 1820-1827

  El Sedfy, Abraham ^b   Dixon, Matthew ^c   Seevaratnam, Rajini ^a   Bocicariu, Alina ^a   Cardoso, Roberta ^a   Mahar, Alyson ^a,e   Kiss, Alex ^f   Helyer, Lucy ^g   Law, Calvin ^a,d   Coburn, Natalie G ^a,d,h  

^a Canada   (Canada)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c MAIMONIDES MEDICAL CENTER   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; GASTRECTOMY; HUMAN; LYMPH NODE DISSECTION; META ANALYSIS; PATHOLOGY; PERSONALIZED MEDICINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH NEOPLASMS;

ADENOCARCINOMA; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; PRECISION MEDICINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 84940002039     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4168-6     Document Type: Article

References (46)

1. World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence Worldwide in 2012. 2012. http://globocan.iarc.fr/Default.aspx. Accessed 10 Aug 2014.
2. Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat. 2011;43(1):1–11.
3. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut. 2002;50(3):378–81.
4. Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010;251(4):640–6.
5. Brar S, Law C, McLeod R, et al. Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. J Am Coll Surg. 2013;217(2), 347.
6. Coburn NG, Lourenco LG, Rossi SE, et al. Management of gastric cancer in Ontario. J Surg Oncol. 2010;102(1):54–63.
7. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
8. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.
9. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37.
10. Takahari D, Hamaguchi T, Yoshimura K, et al. Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer. Gastric Cancer. 2013;17(2):383–6.
11. Sano T. Tailoring treatments for curable gastric cancer. Br J Surg. 2007;94(3):263–4.
12. Zhou D, Quan Z, Wang J, Zhao M, Yang Y. Laparoscopic-assisted versus open distal gastrectomy with D2 lymph node resection for advanced gastric cancer: effect of learning curve on short-term outcomes. A meta-analysis. J Laparoendosc Adv Surg Tech A. 2014;24(3):139–50.
13. Fujii M, Sasaki J, Nakajima T. State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress. Gastric Cancer. 1999;2(3):151–7.
14. Kinoshita T, Maruyama K, Sasako M, Okajima K. Treatment results of gastric cancer patients: Japanese experience. In: Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E, editors. Gastric Cancer. Tokyo: Springer; 1993. p. 319–30.
15. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg. 1987;11(4):418–25.
16. Soga J, Kobayashi K, Saito J, Fujimaki M, Muto T. The role of lymphadenectomy in curative surgery for gastric cancer. World J Surg. 1979;3(6):701–8.
17. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.
18. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7(4):309–15.
19. Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745–8.
20. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79(9-10):1522–30.
21. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.
22. Edwards P, Blackshaw GR, Lewis WG, Barry JD, Allison MC, Jones DR. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma. Br J Cancer. 2004;90(10):1888–92.
23. Degiuli M, Sasako M, Ponti A, Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97(5):643–9.
24. Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101(2):23–31.
25. Seevaratnam R, Bocicariu A, Cardoso R, et al. A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer. 2012;15(Suppl 1):S60-9.
26. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1998;1:10–24.
27. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg (London, Engl). 2011;9(8):672–7.
28. Hyde CJ, Stanworth SJ, Murphy MF. Can you see the wood for the trees? Making sense of forest plots in systematic reviews 2. Analysis of the combined results from the included studies. Transfusion. 2008;48(4):580–3.
29. Hyde CJ, Stanworth SJ, Murphy MF. Can you see the wood for the trees? Making sense of forest plots in systematic reviews. Transfusion. 2008;48(2):218–20.
30. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–14.
31. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995–9.
32. Degiuli M, Sasako M, Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97(5):643–9.
33. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22(11):2069–77.
34. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg. 2004;91(3):283–7.
35. Degiuli M, Sasako M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol. 2004;30(3):303–8.
36. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg. 1988;75(2):110–2.
37. Mansfield PF. Lymphadenectomy for gastric cancer. J Clin Oncol. 2004;22(14):2759–61.
38. Martin RC, 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg. 2002;236(2):159–65.
39. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24(14):2188–96.
40. Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer. 2006;107(9):2143–51.
41. Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery. 2002;131(1):6–15.
42. Walsh M, Srinathan SK, McAuley DF, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol. 2014;67(6):622–8.
43. Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37.
44. Cuschieri SA, Hanna GB. Meta-analysis of d1 versus d2 gastrectomy for gastric adenocarcinoma: let us move on to another era. Ann Surg. 2014;259(6):e90.
45. Yoon SS, Yang HK. Lymphadenectomy for gastric adenocarcinoma: should west meet east? Oncologist. 2009;14(9):871–82.
46. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Noguchi Y. Is D2 lymph node dissection necessary for early gastric cancer? Ann Surg Oncol. 2002;9(4):401–5.